Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

levodopa, carbidopa, entacapone

Available from:

Orion Corporation

ATC code:

N04BA03

INN (International Name):

levodopa, carbidopa, entacapone

Therapeutic group:

Anti-parkinsonska zdravila

Therapeutic area:

Parkinsonova bolezen

Therapeutic indications:

Corbilta je indicirano za zdravljenje odraslih bolnikov s Parkinsonovo boleznijo in konec odmerek motor nihanja ne ustalile na levodopo/Dope decarboxylase (DDC) inhibitor zdravljenje.

Product summary:

Revision: 10

Authorization status:

Pooblaščeni

Authorization date:

2013-11-11

Patient Information leaflet

                                21
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
_Škatla_
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finska
_Nalepka_
Orion Corporation
12.
ŠTEVILK(E) DOVOLJENJ(A) ZA PROMET
EU/1/13/859/001 10 filmsko obloženih tablet
EU/1/13/859/002 30 filmsko obloženih tablet
EU/1/13/859/003 100 filmsko obloženih tablet
EU/1/13/859/004 130 filmsko obloženih tablet
EU/1/13/859/005 175 filmsko obloženih tablet
EU/1/13/859/006 250 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Številka serije:
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
corbilta 50/12,5/200 mg_ [samo škatla]_
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako._ [samo
škatla]_
22
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
_[samo škatla]:_
PC {številka}
SN {številka}
< NN {številka}>
23
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI
NALEPKA NA STEKLENIČKI IN BESEDILO NA ZUNANJI OVOJNINI
1.
IME ZDRAVILA
Corbilta 75 mg/18,75 mg/200 mg filmsko obložene tablete
levodopa/karbidopa/entakapon
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 75 mg levodope, 18,75 mg
karbidope in 200 mg entakapona.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje saharozo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
_Škatla_
10 filmsko obloženih tablet
30 filmsko obloženih tablet
100 filmsko obloženih tablet
130 filmsko obloženih tablet
175 filmsko obloženih tablet
_Nalepka_
10 tablet
30 tablet
100 tablet
130 tablet
175 tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
24
Uporabno do
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Corbilta 50 mg/12,5 mg/200 mg filmsko obložene tablete
Corbilta 75 mg/18,75 mg/200 mg filmsko obložene tablete
Corbilta 100 mg/25 mg/200 mg filmsko obložene tablete
Corbilta 125 mg/31,25 mg/200 mg filmsko obložene tablete
Corbilta 150 mg/37,5 mg/200 mg filmsko obložene tablete
Corbilta 175 mg/43,75 mg/200 mg filmsko obložene tablete
Corbilta 200 mg/50 mg/200 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
50 mg/12,5 mg/200 mg
Ena tableta vsebuje 50 mg levodope, 12,5 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 1,2 mg saharoze.
75 mg/18,75 mg/200 mg
Ena tableta vsebuje 75 mg levodope, 18,75 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 1,4 mg saharoze.
100 mg/25 mg/200 mg
Ena tableta vsebuje 100 mg levodope, 25 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 1,6 mg saharoze.
125 mg/31,25 mg/200 mg
Ena tableta vsebuje 125 mg levodope, 31,25 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 1,6 mg saharoze.
150 mg/37,5 mg/200 mg
Ena tableta vsebuje 150 mg levodope, 37,5 mg karbidope in 200 mg
entakapona.
Pomožne snovi z znanim učinkom:
Ena tableta vsebuje 1,9 mg saharoze in 2,6 mg natrija, kot sestavina
pomožne snovi.
175 mg/43,75 mg/200 mg
Ena tableta vsebuje 175 mg levodope, 43,75 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 1,89 mg saharoze.
200 mg/50 mg/200 mg
Ena tableta vsebuje 200 mg levodope, 50 mg karbidope in 200 mg
entakapona.
Pomožna snov z znanim učinkom:
Ena tableta vsebuje 2,3 mg saharoze.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
50 mg/12,5 mg/200 mg
Rjavkaste ali sivkasto-rdeče okrogle konveksne filmsko obložene
tablete brez zareze z oznako “LCE
50” na eni strani.
75 mg/18,75 mg/200 mg
Svetlorjavkasto rdeče ovalne filmsko
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2023
Public Assessment Report Public Assessment Report Bulgarian 14-11-2014
Patient Information leaflet Patient Information leaflet Spanish 16-01-2023
Public Assessment Report Public Assessment Report Spanish 14-11-2014
Patient Information leaflet Patient Information leaflet Czech 16-01-2023
Public Assessment Report Public Assessment Report Czech 14-11-2014
Patient Information leaflet Patient Information leaflet Danish 16-01-2023
Public Assessment Report Public Assessment Report Danish 14-11-2014
Patient Information leaflet Patient Information leaflet German 16-01-2023
Public Assessment Report Public Assessment Report German 14-11-2014
Patient Information leaflet Patient Information leaflet Estonian 16-01-2023
Public Assessment Report Public Assessment Report Estonian 14-11-2014
Patient Information leaflet Patient Information leaflet Greek 16-01-2023
Public Assessment Report Public Assessment Report Greek 14-11-2014
Patient Information leaflet Patient Information leaflet English 16-01-2023
Public Assessment Report Public Assessment Report English 14-11-2014
Patient Information leaflet Patient Information leaflet French 16-01-2023
Public Assessment Report Public Assessment Report French 14-11-2014
Patient Information leaflet Patient Information leaflet Italian 16-01-2023
Public Assessment Report Public Assessment Report Italian 14-11-2014
Patient Information leaflet Patient Information leaflet Latvian 16-01-2023
Public Assessment Report Public Assessment Report Latvian 14-11-2014
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2023
Public Assessment Report Public Assessment Report Lithuanian 14-11-2014
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2023
Public Assessment Report Public Assessment Report Hungarian 14-11-2014
Patient Information leaflet Patient Information leaflet Maltese 16-01-2023
Public Assessment Report Public Assessment Report Maltese 14-11-2014
Patient Information leaflet Patient Information leaflet Dutch 16-01-2023
Public Assessment Report Public Assessment Report Dutch 14-11-2014
Patient Information leaflet Patient Information leaflet Polish 16-01-2023
Public Assessment Report Public Assessment Report Polish 14-11-2014
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2023
Public Assessment Report Public Assessment Report Portuguese 14-11-2014
Patient Information leaflet Patient Information leaflet Romanian 16-01-2023
Public Assessment Report Public Assessment Report Romanian 14-11-2014
Patient Information leaflet Patient Information leaflet Slovak 16-01-2023
Public Assessment Report Public Assessment Report Slovak 14-11-2014
Patient Information leaflet Patient Information leaflet Finnish 16-01-2023
Public Assessment Report Public Assessment Report Finnish 14-11-2014
Patient Information leaflet Patient Information leaflet Swedish 16-01-2023
Public Assessment Report Public Assessment Report Swedish 14-11-2014
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2023
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2023
Patient Information leaflet Patient Information leaflet Croatian 16-01-2023
Public Assessment Report Public Assessment Report Croatian 14-11-2014

Search alerts related to this product